journal
https://read.qxmd.com/read/39264338/imaging-in-vasculitis
#1
JOURNAL ARTICLE
Orrin M Troum, Olga L Pimienta, Alvin Wells
PURPOSE OF REVIEW: Systemic vasculitides are characterized by inflammation of blood vessels. Their classification is based on the size of the blood vessels involved - large, medium, or small. Vasculitis early diagnosis and reliable monitoring are crucial to establish a treatment plan and prevent serious complications. Based on these considerations and depending on the location of the affected vessels, the importance of imaging modalities including ultrasonography (US), magnetic resonance Imaging (MRI), magnetic resonance angiography (MRA), computed tomography (CT), computed tomography angiography (CTA), and [18F]-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (FDG-PET/CT) has progressively increased...
September 13, 2024: Current Opinion in Rheumatology
https://read.qxmd.com/read/39258603/the-role-of-neutrophil-extracellular-traps-in-inflammatory-rheumatic-diseases
#2
JOURNAL ARTICLE
Norio Hanata, Mariana J Kaplan
PURPOSE OF REVIEW: Dysregulation in neutrophil extracellular trap (NET) formation and degradation has been reported in several inflammatory rheumatic diseases. This review summarizes the recent advances in the understanding the role of NETs in the context of inflammatory rheumatic diseases. RECENT FINDINGS: NET formation is enhanced in peripheral blood of patients with large vessel vasculitis and polymyalgia rheumatica. NETs are detected in affected organs in autoimmune conditions, and they might play pathological roles in tissues...
September 12, 2024: Current Opinion in Rheumatology
https://read.qxmd.com/read/39193877/gastrointestinal-disease-in-systemic-sclerosis-the-neglected-organ-system
#3
JOURNAL ARTICLE
Zsuzsanna McMahan, John Pandolfino, Harris Perlman, Francesco Del Galdo, Monique Hinchcliff
PURPOSE OF REVIEW: Identifying outcomes and clinical trial endpoints enabled the discovery of new inflammatory bowel disease (IBD) treatments. Herein, we describe efforts to advance the study of gastrointestinal (GI) manifestations in systemic sclerosis (SSc). RECENT FINDINGS: Insights into the scope of the problem, as well as advancements in the measurement and treatment of SSc-GI, are underway. Proposed SSc esophageal endophenotypes are now defined, risk stratification methods are growing, and imaging and functional studies are now employed to guide therapeutic interventions...
August 29, 2024: Current Opinion in Rheumatology
https://read.qxmd.com/read/39193880/treatment-of-interstitial-lung-disease-in-systemic-sclerosis-guidelines-and-new-clinical-trial-results
#4
JOURNAL ARTICLE
Sindhu R Johnson, Elana J Bernstein
PURPOSE OF REVIEW: Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). The American College of Rheumatology (ACR), in conjunction with the American College of Chest Physicians (CHEST), recently published clinical practice guidelines for the treatment of adults with systemic autoimmune rheumatic disease-associated ILD, including SSc-ILD. Herein, we summarize evidence from randomized trials evaluating the safety and efficacy of pharmacologic therapies for the treatment of SSc-ILD...
August 28, 2024: Current Opinion in Rheumatology
https://read.qxmd.com/read/39189041/understanding-the-gastrointestinal-microbiome-in-systemic-sclerosis-methodological-advancements-and-emerging-research
#5
JOURNAL ARTICLE
Alana J Haussmann, Zsuzsanna H McMahan, Elizabeth R Volkmann
PURPOSE OF REVIEW: This review highlights the role of the gastrointestinal (GI) microbiome in systemic sclerosis (SSc). We describe techniques for evaluating the GI microbiome in humans, and emerging research linking GI microbiome alterations (i.e., dysbiosis) and distinct SSc clinical manifestations. We also address the evolving treatment landscape targeting dysbiosis in SSc. RECENT FINDINGS: Recent literature brings into focus the complex relationship between the GI microbiome and SSc pathogenesis...
August 26, 2024: Current Opinion in Rheumatology
https://read.qxmd.com/read/39171605/current-approach-to-muscle-imaging-in-myositis
#6
JOURNAL ARTICLE
Didem Saygin, Jemima Albayda
PURPOSE OF REVIEW: Muscle imaging is commonly utilized in idiopathic inflammatory myopathies (IIM) for diagnostic evaluation, selection of muscle biopsy site, and differentiating between disease activity versus damage. In this review, we discuss the current state and recent developments in the use of muscle imaging modalities including muscle magnetic resonance imaging (MRI), ultrasound (US), and positron emission tomography (PET) scan. RECENT FINDINGS: Muscle MRI is a clinically useful tool in evaluation of IIM with studies showing good correlations between pattern of morphological changes on MRI and histopathological findings on muscle biopsy...
August 23, 2024: Current Opinion in Rheumatology
https://read.qxmd.com/read/39171604/cross-tissue-organization-of-myeloid-cells-in-scleroderma-and-related-fibrotic-diseases
#7
JOURNAL ARTICLE
Ian D Odell
PURPOSE OF REVIEW: Scleroderma and other fibrotic diseases have been investigated using single-cell RNA sequencing (scRNA-Seq), which has demonstrated enrichment in myeloid cell populations in multiple tissues. However, scRNA-Seq studies are inconsistent in their nomenclature of myeloid cell types, including dendritic cells, monocytes, and macrophages. Using cell type-defining gene signatures, I propose a unified nomenclature through analysis of myeloid cell enrichment across fibrotic tissues...
August 23, 2024: Current Opinion in Rheumatology
https://read.qxmd.com/read/39171583/clinical-endpoints-in-myositis-challenges-and-ways-forward
#8
JOURNAL ARTICLE
Cristina Ricco, Caroline J Stone, Victoria P Werth
PURPOSE OF REVIEW: This review addresses the challenges and advances in clinical endpoints for myositis, with a particular focus on ensuring comprehensive assessment of both muscle and skin disease activity. The relevance of this review stems from recent developments in outcome measures and their implications for clinical trial design and patient inclusivity. While quality of life (QoL) and lung involvement are also important aspects of myositis, they are beyond the scope of this review and need to be addressed in future studies...
August 23, 2024: Current Opinion in Rheumatology
https://read.qxmd.com/read/39155767/autoantibody-testing-in-myositis-an-update
#9
JOURNAL ARTICLE
Fionnuala K McMorrow, Natalie Anwyll, Sarah L Tansley
PURPOSE OF REVIEW: This review aims to provide an update on myositis autoantibody testing strategies. We have focussed on the reliability and usefulness of different myositis autoantibody detection methods, including commonly used solid phase immunoassays and newer discovery techniques. RECENT FINDINGS: Several studies have highlighted the limitations of currently available immunoassays, particularly when used in populations with low pretest probability and without supporting clinical evidence...
August 20, 2024: Current Opinion in Rheumatology
https://read.qxmd.com/read/39137051/from-traditional-to-targeted-the-changing-trajectory-of-therapies-in-dermatomyositis
#10
JOURNAL ARTICLE
Rochelle L Castillo, Kimberly Hashemi, Elizabeth Rainone, Katharina S Shaw, Ruth Ann Vleugels
PURPOSE OF REVIEW: New breakthroughs in our understanding of dermatomyositis (DM) have spawned the recent development of novel agents that specifically target key drivers in DM immunopathogenesis. This review aims to provide a comprehensive overview of new and forthcoming therapies for DM and to highlight their mechanisms of action, best evidence to date, and potential impact on disease management. RECENT FINDINGS: Strategies that either counteract dysregulated interferon signaling [via the inhibition of interferon β, the type I interferon receptor subunit 1 (IFNAR1), or janus kinase (JAK)-signal transducer and activator of transcription (STAT) transduction] or induce durable autoreactive B cell depletion through chimeric antigen receptor (CAR) T-cell therapy appear to hold the most promise for sustained remission in DM...
August 14, 2024: Current Opinion in Rheumatology
https://read.qxmd.com/read/39132766/current-efforts-and-historical-perspectives-on-classification-of-idiopathic-inflammatory-myopathies
#11
JOURNAL ARTICLE
Stefanie Glaubitz, Didem Saygin, Ingrid E Lundberg
PURPOSE OF REVIEW: The classification of idiopathic inflammatory myopathies is challenging due to the large number of clinical, serological, histopathological and genetic findings, as well as the latest findings and developments in the field of myositis research. The latest official classification criteria are the 2017 European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) classification criteria for adult and juvenile idiopathic inflammatory myopathies, which have been extensively reviewed in recent years for their applicability, sensitivity and specificity...
August 13, 2024: Current Opinion in Rheumatology
https://read.qxmd.com/read/39132763/interstitial-lung-disease-and-myositis
#12
JOURNAL ARTICLE
Takahisa Gono, Masataka Kuwana
PURPOSE OF REVIEW: In patients with myositis, interstitial lung disease (ILD) is one of the major causes of morbidity and mortality. Given the limited evidence, there is an urgent need to refine the treatment for myositis-ILD. This review aims to highlight recent updates on the management of myositis-associated ILD, focusing on screening, risk stratification, and treatment. RECENT FINDINGS: Asian race and/or residence, dermatomyositis, mechanic's hand, antisynthetase antibodies, and antimelanoma differentiation-associated gene 5 antibodies are risk factors for ILD development...
August 13, 2024: Current Opinion in Rheumatology
https://read.qxmd.com/read/39120541/heart-involvement-in-systemic-sclerosis-emerging-concepts
#13
JOURNAL ARTICLE
Jessica L Fairley, Laura Ross, Mandana Nikpour
PURPOSE OF REVIEW: Systemic sclerosis (SSc)-associated heart involvement (SHI) is a significant cause of both morbidity and mortality in individuals with SSc. SHI can take many different forms, and likely is a spectrum of fibroinflammatory cardiac disease. Presenting features include arrhythmia, ventricular systolic or diastolic dysfunction, pericardial disease, and exercise intolerance. Risk of sudden cardiac death in SSc is likely 10-30-fold greater than general population estimates...
August 12, 2024: Current Opinion in Rheumatology
https://read.qxmd.com/read/39115431/advances-in-the-diagnosis-of-multiorgan-involvement-in-systemic-sclerosis-a-focus-on-mri
#14
JOURNAL ARTICLE
Attila Feher, Francesco Del Galdo, Sven Plein
PURPOSE OF REVIEW: Systemic sclerosis (SSc) is a rare chronic multisystem autoimmune disease characterized by endothelial dysfunction, tissue hypoxia, and diffuse organ fibrosis. MRI provides a radiation free approach to noninvasively assess the key manifestations of SSc in multiple organs. The purpose of this review is to summarize recent advances in MRI techniques to provide diagnostic and prognostic information in patients with SSc. RECENT FINDINGS: MRI can probe processes that play a key role in the development of SSc-related complications, including neointima proliferation, fibrosis, and hypoxia...
August 8, 2024: Current Opinion in Rheumatology
https://read.qxmd.com/read/39120537/calcinosis-in-dermatomyositis
#15
JOURNAL ARTICLE
Srijana Davuluri, Lorinda Chung, Christian Lood
PURPOSE OF REVIEW: To provide the most recent literature on our understanding behind the pathogenesis and the treatment of calcinosis in dermatomyositis. RECENT FINDINGS: Early diagnosis and controlling the overall disease activity are cornerstones to prevent calcinosis in juvenile dermatomyositis. Observational cohort studies showed that prolonged state of inflammation and features of vascular dysfunction like digital ulcers and abnormal nailfold capillaries are associated with calcinosis...
July 25, 2024: Current Opinion in Rheumatology
https://read.qxmd.com/read/39046085/autoantibodies-as-putative-biomarkers-and-triggers-of-cell-dysfunctions-in-systemic-sclerosis
#16
JOURNAL ARTICLE
Irene Rosa, Eloisa Romano, Bianca Saveria Fioretto, Mirko Manetti
PURPOSE OF REVIEW: Antinuclear autoantibodies represent a serological hallmark of systemic sclerosis (SSc), with anticentromere, antitopoisomerase-I, and anti-RNA polymerase III antibodies routinely assessed for diagnosis, clinical subset classification, and prognosis. In addition, an increasing number of autoantibodies have been demonstrated to play a pathogenic role by mediating different SSc manifestations. This review aims to give an overview on autoantibodies as putative biomarkers in SSc and discuss their possible pathogenic role as triggers of cell dysfunctions...
July 25, 2024: Current Opinion in Rheumatology
https://read.qxmd.com/read/39007238/antimelanoma-differentiation-antigen-5-positive-dermatomyositis-an-update
#17
JOURNAL ARTICLE
Xin Lu, Qinglin Peng, Guochun Wang
PURPOSE OF REVIEW: Antimelanoma differentiation antigen 5-dermatomyositis (MDA5-DM) is a complex and serious systemic autoimmune disease that primarily affects the skin and lungs. In this review, we aimed to provide new insights into the clinical features, pathogenesis, and practical management approach for this disease. RECENT FINDINGS: Although lung lesions are prominent in most patients with MDA5-DM, they are now recognized as heterogeneous diseases. Peripheral blood lymphocyte count can serve as a simple and reliable laboratory parameter for categorizing MDA5-DM into three subgroups: mild, medium, and severe...
July 16, 2024: Current Opinion in Rheumatology
https://read.qxmd.com/read/39007236/sglt-2-inhibitors-new-horizons-for-rheumatologists
#18
JOURNAL ARTICLE
Katherine Chakrabarti, W Joseph McCune
PURPOSE OF REVIEW: Sodium glucose cotransporter 2 (SGLT2) inhibitors are a class of medications initially developed for the treatment of diabetes, although their cardiac and renal protective benefits are far reaching. There has been marked interest in the rheumatology community to adopt these medications into our clinical practice, particularly for chronic kidney disease with persistent proteinuria. RECENT FINDINGS: SGLT2 inhibitors have been approved for patients with type 2 diabetes mellitus, heart failure with reduced or preserved ejection fraction, atherosclerotic cardiovascular disease in the setting of type 2 diabetes mellitus, as well as chronic kidney disease with proteinuria...
July 16, 2024: Current Opinion in Rheumatology
https://read.qxmd.com/read/38990100/update-on-antineutrophil-cytoplasmic-autoantibody-vasculitis-in-children
#19
JOURNAL ARTICLE
Jessica L Bloom, Eveline Y Wu
PURPOSE OF REVIEW: Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is often organ- or life-threatening in children and impacts them during important periods of psychosocial and physical development. This review covers recent advances in the pathophysiology, diagnosis, management, and outcomes of AAV in children and highlights the ongoing need for funding and increased research collaboration. RECENT FINDINGS: Recent work has improved our understanding of AAV disease pathogenesis, potentially identifying new biomarkers and therapeutic targets...
July 11, 2024: Current Opinion in Rheumatology
https://read.qxmd.com/read/39082208/editorial-introduction
#20
EDITORIAL
(no author information available yet)
No abstract text is available yet for this article.
September 1, 2024: Current Opinion in Rheumatology
journal
journal
30327
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.